These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 4871272)
1. [Remarkable action of vincaleukoblastine in the treatment of a case of malignant cutaneous reticulosis]. Marill FG; Grould P Bull Soc Fr Dermatol Syphiligr; 1967; 74(5):589-91. PubMed ID: 4871272 [No Abstract] [Full Text] [Related]
2. [The effectiveness of treating dermal reticulosis with prospidin and fotrin]. Mukhamedov N Vestn Dermatol Venerol; 1973 Jan; 47(1):49-52. PubMed ID: 4575610 [No Abstract] [Full Text] [Related]
4. [Experience in treating certain forms of reticulodermia with the new Soviet cytostaic preparation fotrin]. Smelov NS; Kalamkarian AA; Mukhamedov N Vestn Dermatol Venerol; 1973 Dec; 47(12):9-12. PubMed ID: 4597540 [No Abstract] [Full Text] [Related]
5. [Failure of vincaleucoblastine in the treatment of a case of malignant histio-monocytic reticulosis]. Marill FG; Grould P Bull Soc Fr Dermatol Syphiligr; 1969; 76(2):200-2. PubMed ID: 5403402 [No Abstract] [Full Text] [Related]
6. Response of nodular non-X histiocytosis to vinblastine. Winkelmann RK; Hu CH; Kossard S Arch Dermatol; 1982 Nov; 118(11):913-7. PubMed ID: 7138050 [TBL] [Abstract][Full Text] [Related]
7. [The role of vinblastine in the treatment of malignant lymphomas]. Eridani S; Esposito R; Ponti GB; Giangrande A Cancro; 1968; 21():Suppl 6:102+. PubMed ID: 4906143 [No Abstract] [Full Text] [Related]
8. [Vincaleukoblastine in the therapy of malignant neoplasms]. Rotolo V Friuli Med; 1968; 23(1):31-52. PubMed ID: 4910040 [No Abstract] [Full Text] [Related]
9. [Very late malignant transformation of papullar reticulosis with a prolonged development (lymphomatoid papulosis)]. Dupont A Ann Dermatol Syphiligr (Paris); 1973; 100(2):141-6. PubMed ID: 4578545 [No Abstract] [Full Text] [Related]
10. [Value of vincaleukoblastine in the treatment of Hodgkin's disease and other hematosarcomas and leukemias]. Mathé G; Schweisguth O; Schneider M; Amiel JL; Cattan A; Schwarzenberg L; Brulé G; Smadja R Sem Ther; 1964 May; 40(5):320-4. PubMed ID: 4861409 [No Abstract] [Full Text] [Related]
11. [Evolution of histopathologic changes and clinical manifestations in primary reticulosis of the skin]. Kodolova IM; Potekaev NS Arkh Patol; 1971; 33(8):55-61. PubMed ID: 4945624 [No Abstract] [Full Text] [Related]
17. [Experience with vinblastine in the treatment of lymphoblastomas]. Capretti G Cancro; 1968; 21():Suppl 6:93-7. PubMed ID: 4906146 [No Abstract] [Full Text] [Related]
18. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581 [TBL] [Abstract][Full Text] [Related]
19. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. Grange F; Maubec E; Bagot M; Beylot-Barry M; Joly P; Dalle S; Delaporte E; Dereure O; Bachelez H; Vergier B; Petrella T; D'Incan M Arch Dermatol; 2009 Mar; 145(3):329-30. PubMed ID: 19289772 [No Abstract] [Full Text] [Related]